sur OXURION (EBR:OXUR)
Oxurion considers acquiring a CRO to strengthen its strategy
Oxurion NV, a Leuven-based biopharmaceutical company, has signed a letter of intent to acquire a majority stake in a French Contract Research Organization (CRO). Specializing in clinical development, the target company is a key player in research services and regulatory affairs. This transaction, valued at €1,037,500, is part of Oxurion's strategy to offer an integrated solution to the pharmaceutical and biotechnology industries.
The CRO, based in the Paris region, brings its expertise in clinical trial design and scientific communication. Oxurion plans to integrate this new skill to strengthen its value chain, complementing its recently acquired Axiodis. This merger would allow Oxurion to offer joint solutions and optimize its support for sponsors.
The transaction is expected to close in February 2026, subject to due diligence. Oxurion expects this integration to boost profitability and enable significant revenue growth.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de OXURION